glp-1 receptor agonist medicines The Impact of Agonists on Sedation Benefits and Risks of GLP-1
Description
Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025
The hazard ratio was 7.64 (95% CI, 2.21-26.36
Liraglutide, semaglutide and dulaglutide have demonstrated cardiovascular benefits, and Wegovy recently added to this evidence base: in the SELECT trial, patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo
The long-acting GLP-1 agonist segment dominated the market in 2025 owing to its superior dosing convenience, improved patient observation, and sustained therapeutic efficacy
Accessed 3 Nov 2025
